Corvus Pharmaceuticals (CRVS) Price & Analysis

Compare

643 Followers

CRVS Stock Chart & Stats

$7.84

-$0.10(-1.74%)

At close: Jan 08 4:00 PM EST

$7.84

-$0.10(-1.74%)

Day’s Range― - ―

52-Week Range$2.54 - $9.60

Previous CloseN/A

Volume202.27K

Average Volume (3M)1.09M

Market Cap

$592.97M

Enterprise Value$545.83M

Total Cash (Recent Filing)$65.69M

Total Debt (Recent Filing)$1.01M

Price to Earnings (P/E)―

Beta1.07

Next Earnings

Mar 05, 2026

EPS Estimate

-0.13

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding74,681,870

10 Day Avg. Volume1,464,037

30 Day Avg. Volume1,094,951

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)10.02

Price to Sales (P/S)0.00

P/FCF Ratio-12.83

Enterprise Value/Market Cap0.92

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-14.23

Forecast

1Y Price Target

$13.33

Price Target Upside70.03% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-0.43

Revenue Forecast (FY)$620.00K

Bulls Say, Bears Say

Bulls Say

Clinical TrialsMajor clinical readouts expected in the next 12 months, with three major clinical results anticipated in 2026.

Drug DevelopmentCorvus Pharmaceuticals is advancing its atopic dermatitis clinical program and is ready to move soquelitinib into a Phase 2 study following strong results.

Regulatory ApprovalsThe company's partner in China, Angel Pharmaceuticals, has received regulatory clearance to initiate a Phase 1/2 study in China, expanding the geographical scope of clinical testing.

Bears Say

Financial PerformanceThe company reported no revenues for the quarter, in-line with the consensus estimate.

Corvus Pharmaceuticals News

Corvus presents final data from soquelitinib Phase 1/1b T cell lymphoma trial

Corvus Pharmaceuticals (CRVS) announced the presentation of final data from its Phase 1/1b trial of soquelitinib in patients...

10d ago

CRVS

Corvus Pharmaceuticals management to meet with Cantor

Group Dinner Meeting with Management in conjunction with American Society of Hematology (ASH) Annual Meeting to be held...

14d ago

CRVS

Corvus Pharmaceuticals Reports Positive Q3 Earnings Call

Corvus Pharmaceuticals Inc. (($CRVS)) has held its Q3 earnings call. Read on for the main highlights of the...

1M ago

CRVS

Corvus Pharmaceuticals Advances Clinical Trials for Soquelitinib

Corvus Pharmaceuticals Inc. ( ($CRVS) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

CRVS

Corvus Pharmaceuticals reports Q3 EPS (12c), consensus (12c)

“We are advancing the development of our ITK inhibitor, soquelitinib, in both atopic dermatitis and T cell lymphomas....

1M ago

CRVS

Corvus Pharmaceuticals price target raised to $13 from $11 at Mizuho

Mizuho raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $13 from $11 and keeps an Outperform...

2M ago

CRVS

CRVS Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Corvus Pharmaceuticals Inc. (CRVS) is scheduled to report 3rd quarter earnings on 10/30/2025. Regarding Q3 estimates, Wall Street...

2M ago

CRVS

Corvus Pharmaceuticals’ Soquelitinib Study: A Potential Game-Changer for Atopic Dermatitis

Corvus Pharmaceuticals Inc. (($CRVS)) announced an update on their ongoing clinical study. Corvus Pharmaceuticals Inc. is conducting a...

2M ago

CRVS

Corvus Pharmaceuticals’ Phase 3 Study on Soquelitinib: A Potential Game-Changer in Lymphoma Treatment

Corvus Pharmaceuticals Inc. (($CRVS)) announced an update on their ongoing clinical study. Study Overview: Corvus Pharmaceuticals Inc. is...

2M ago

CRVS

Corvus Pharmaceuticals initiated with an Overweight at Barclays

Barclays initiated coverage of Corvus Pharmaceuticals (CRVS) with an Overweight rating and $16 price target The firm launched...

2M ago

CRVS

Corvus Pharmaceuticals Appoints David Moore as Director

Corvus Pharmaceuticals ( ($CRVS) ) just unveiled an announcement. On October 2, 2025, Corvus Pharmaceuticals appointed David Moore...

3M ago

CRVS

Corvus Pharmaceuticals’ Earnings Call Highlights Progress

Corvus Pharmaceuticals Inc. (($CRVS)) has held its Q2 earnings call. Read on for the main highlights of the...

4M ago

CRVS

Corvus Pharmaceuticals’ Clinical Advancements and Strategic Collaborations Boost Investor Confidence

H.C. Wainwright analyst Sean Lee CFA maintained a Buy rating on Corvus Pharmaceuticals today and set a price...

4M ago

CRVS

Corvus Pharmaceuticals price target lowered to $15 from $17 at Oppenheimer

Oppenheimer analyst Jeff Jones lowered the firm’s price target on Corvus Pharmaceuticals (CRVS) to $15 from $17 and...

4M ago

CRVS

CRVS FAQ

What was Corvus Pharmaceuticals Inc’s price range in the past 12 months?

Corvus Pharmaceuticals Inc lowest stock price was $2.54 and its highest was $9.60 in the past 12 months.

What is Corvus Pharmaceuticals Inc’s market cap?

Corvus Pharmaceuticals Inc’s market cap is $592.97M.

When is Corvus Pharmaceuticals Inc’s upcoming earnings report date?

Corvus Pharmaceuticals Inc’s upcoming earnings report date is Mar 05, 2026 which is in 77 days.

How were Corvus Pharmaceuticals Inc’s earnings last quarter?

Corvus Pharmaceuticals Inc released its earnings results on Nov 04, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.127 by $0.007.

Is Corvus Pharmaceuticals Inc overvalued?

According to Wall Street analysts Corvus Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Corvus Pharmaceuticals Inc pay dividends?

Corvus Pharmaceuticals Inc does not currently pay dividends.

What is Corvus Pharmaceuticals Inc’s EPS estimate?

Corvus Pharmaceuticals Inc’s EPS estimate is -0.13.

How many shares outstanding does Corvus Pharmaceuticals Inc have?

Corvus Pharmaceuticals Inc has 74,681,870 shares outstanding.

What happened to Corvus Pharmaceuticals Inc’s price movement after its last earnings report?

Corvus Pharmaceuticals Inc reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.127. Following the earnings report the stock price went down -1.44%.

Which hedge fund is a major shareholder of Corvus Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in CRVS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Corvus Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-35.82%

Trailing 12-Months

Asset Growth

36.83%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

Corvus Pharmaceuticals (CRVS) Earnings & Revenues

Historic Earnings Reports

CRVS Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented significant positive developments, including a notable reduction in net loss, a strong cash position, and successful clinical trial progress for soquelitinib. However, increased R&D expenses and delays in trial result reporting were challenges. Overall, the positive aspects, particularly related to clinical advancements and financial improvements, seem to outweigh the negatives.View all CRVS earnings summaries

CRVS Stock 12 Month Forecast

Average Price Target

$13.33

▲(70.03% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","17":"$17","5.75":"$5.75","9.5":"$9.5","13.25":"$13.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5.75,9.5,13.25,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.51,9.086153846153845,9.662307692307692,10.238461538461538,10.814615384615385,11.39076923076923,11.966923076923077,12.543076923076923,13.119230769230768,13.695384615384615,14.271538461538462,14.847692307692308,15.423846153846153,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.51,8.88076923076923,9.25153846153846,9.622307692307693,9.993076923076924,10.363846153846154,10.734615384615385,11.105384615384615,11.476153846153846,11.846923076923076,12.217692307692307,12.588461538461537,12.95923076923077,{"y":13.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.51,8.701538461538462,8.893076923076922,9.084615384615384,9.276153846153846,9.467692307692307,9.659230769230769,9.850769230769231,10.042307692307691,10.233846153846153,10.425384615384615,10.616923076923076,10.808461538461538,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.09,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.25,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.04,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.17,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.03,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.86,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.26,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.04,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >